• Novavax Inc., of Rockville, Md., said top-line results from two Phase I trials of its A/H5N1 avian influenza vaccine candidate showed that the vaccine is safe and produces immunogenicity with and without adjuvant. It also showed statistically significant adjuvant effects on immune responses.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter